ClinicalTrials.gg
CompletedNCT06971900EPPUpdated Jul 29, 2026

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

A Phase 2 interventional study of PORT-77 and Placebo in Erythropoietic Protoporphyria (EPP), sponsored by Portal Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Portal Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
9th of 13
28 · median 77
Started
2025
with 1 other
Phase 2
5 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
3 of 18
Portal Therapeutics, Inc.

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 15th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)

Keywords

  • PORT-77
  • EPP
  • erythropoietic protoporphyria
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. ≥18.0 and ≤40.0 kg/m2 and weight ≥50 kg on Day -1.
  2. Nonsmoker or willing to refrain from the use of nicotine or tobacco-containing products for at least 30 days prior to the first dose of study drug based on participant self-reporting and agrees to refrain from the use of these products throughout the study.
  3. Known diagnosis of EPP.
  4. History of consistent, non-painful prodrome prior to phototoxic attacks.
  5. Experiences prodrome within 40 minutes of uncovered sunlight exposure.
  6. Willing and able to follow protocol-specified guidance.
  7. Able to read and understand English and is willing and able to provide document to participate in the study at the time of the Remote Screening Visit and at the In-Clinic Screening Visit.
  8. Able to understand the study procedures as described in the ICF and is willing and able to comply with the study requirements.

Major Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems identified or observed during the screening period or expected during the conduct of the study that could lead to difficulty complying with study procedures or interfere with the safe completion of the study.
  2. History or presence of any illness or medical or psychiatric condition or disease that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.
  3. Current alcohol or drug use disorder, as defined by the .
  4. History of gastrointestinal condition, including surgeries, which may affect absorption after oral administration.
  5. History of cancer, with the exception of cutaneous non-melanoma skin cancer (basal or squamous cell carcinoma).
  6. Received another medicine within 5 half-lives, if the half-life is known, or within 28 days, if the half-life is unknown, prior to Day 1.
  7. Surgical procedure planned within 28 days prior to Day 1.
  8. Donation of blood or significant blood loss within 60 days prior to Day 1.
  9. Plasma donation within 7 days prior to Day 1.
  10. Unable to refrain from or anticipates the use of any of the following beginning 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study drug and throughout the study:

    1. Substrates of BCRP or MATE1/2-K
    2. substrates that cannot be separated by at least 2 hours from PORT-77 dosing
    3. Moderate or strong P-gp inhibitors or inducers
    4. Moderate or strong CYP3A4 inhibitors or inducers
    5. Herbal supplements or food products containing grapefruit juice, star fruit, or Seville oranges
    6. Illicit substances (eg, opiates, amphetamines, cocaine, cannabinoids [including prescription medical cannabis]).
  11. With the following exceptions, is unable to refrain from or anticipates the use of any nonprescription medications and herbal/nutritional supplements beginning 14 days prior to the first dose of study drug and throughout the study:

    1. A daily multivitamin
    2. Single use of acetaminophen, aspirin, or ibuprofen at a dose equal to or lower than that recommended on the package
  12. Estimated \<60 mL/min/1.73 m2 using the CKD-EPI equation on Day -1.
  13. In the absence of known mild hepatic impairment, or aspartate aminotransferase ≥3 × , or total ≥2 × ULN (unless documented Gilbert syndrome) on Day -1.
  14. Moderate (Class B) or severe (Class C) hepatic impairment as measured by the score reported historically or calculated on Day -1.
  15. Female participant with a positive pregnancy test on Day -1 or who is breastfeeding.
  16. Positive urine drug or alcohol results on Day -1.
  17. Positive results for , , or antibody and HCV RNA on Day -1. Note, for participants successfully treated for HCV, positive antibody test with external laboratory evidence of negative RNA test is not exclusionary.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    PORT-77

    Active

    Drug: PORT-77

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Active oral dose form

  • DrugPlacebo

    Matching inactive oral dose form

06

What researchers measure

Primary outcomes

  1. Plasma PPIX level

    Change over the course of the study in plasma PPIX concentrations

    Time frame: 9 Days

Secondary outcomes

  1. Safety and tolerability

    Evaluate safety and tolerability of PORT-77 over the course of the study

    Time frame: 9 Days

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last)

    Area under the plasma concentration-time curve from time zero to the last measurable concentration of PORT-77

    Time frame: Day 1 through Day 9

  3. Area Under the Plasma Concentration-Time Curve Over the 12-Hour Dosing Interval at Steady State (AUC0-12)

    Area under the plasma concentration-time curve over the 12-hour dosing interval at steady state.

    Time frame: Up to Day 8

  4. Area Under the Plasma Concentration-Time Curve Over the 24-Hour Dosing Interval at Steady State (AUC0-24)

    Area under the plasma concentration-time curve over the 24-hour dosing interval at steady state.

    Time frame: Up to Day 8

  5. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration of PORT-77

    Time frame: Day 1 through Day 9

  6. Trough Plasma Concentration (Ctrough)

    Observed plasma concentration at the end of the dosing interval.

    Time frame: Up to Day 8

  7. Time to Maximum Observed Plasma Concentration (Tmax)

    Time after dosing at which maximum observed plasma concentration is reached.

    Time frame: Day 1 through Day 9

  8. Time of Last Quantifiable Plasma Concentration (Tlast)

    Time corresponding to the last measurable plasma concentration.

    Time frame: Day 1 through Day 9

  9. Terminal Elimination Half-Life (t½)

    Apparent first-order terminal elimination half-life.

    Time frame: Day 1 through Day 9

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Nov 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
May 14, 2025
StartActual
Apr 4, 2025
Primary completionActual
Nov 22, 2025
CompletionActual
Nov 24, 2025
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06971900
Lead sponsor
Portal Therapeutics, Inc.
Collaborators
Celerion
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Apr 4, 2025
Primary completion
Nov 22, 2025
Completion
Nov 24, 2025
Last update
Jul 29, 2026

Study contacts

Chief Medical Officer
study director · Portal Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PORT-77

Start the discussion